Scholar Rock Holding Corp (SRRK)

$9.39

-0.31

(-3.2%)

Market is closed - opens 7 PM, 13 Jun 2024

Insights on Scholar Rock Holding Corp

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 78.6% return, outperforming this stock by 44.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 235.8% return, outperforming this stock by 305.1%

Performance

  • $9.15
    $10.16
    $9.39
    downward going graph

    2.53%

    Downside

    Day's Volatility :9.91%

    Upside

    7.58%

    downward going graph
  • $5.93
    $21.17
    $9.39
    downward going graph

    36.85%

    Downside

    52 Weeks Volatility :71.99%

    Upside

    55.64%

    downward going graph

Returns

PeriodScholar Rock Holding CorpSector (Health Care)Index (Russel 2000)
3 Months
-41.6%
-0.5%
0.0%
6 Months
-47.57%
9.6%
0.0%
1 Year
34.54%
11.8%
0.0%
3 Years
-69.75%
17.5%
-24.3%

Highlights

Market Capitalization
768.0M
Book Value
$2.29
Earnings Per Share (EPS)
-2.09
Wall Street Target Price
27.14
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-40.64%
Return On Equity TTM
-89.09%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
-89.9M
EBITDA
-186.5M
Diluted Eps TTM
-2.09
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.38
EPS Estimate Next Year
-2.12
EPS Estimate Current Quarter
-0.51
EPS Estimate Next Quarter
-0.51

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Scholar Rock Holding Corp(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
14
13
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 189.03%

Current $9.39
Target $27.14

Technicals Summary

Sell

Neutral

Buy

Scholar Rock Holding Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Scholar Rock Holding Corp
Scholar Rock Holding Corp
-28.89%
-47.57%
34.54%
-69.75%
-44.54%
Moderna, Inc.
Moderna, Inc.
18.08%
90.15%
20.13%
-28.46%
810.37%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.44%
16.99%
34.02%
91.12%
230.07%
Novo Nordisk A/s
Novo Nordisk A/s
7.08%
47.38%
78.63%
235.88%
440.46%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
12.0%
34.61%
41.38%
147.19%
182.21%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Scholar Rock Holding Corp
Scholar Rock Holding Corp
NA
NA
NA
-2.38
-0.89
-0.41
NA
2.29
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.16
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.56
29.56
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.53
49.53
2.36
3.48
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.34
31.34
0.53
17.08
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Scholar Rock Holding Corp
Scholar Rock Holding Corp
Buy
$768.0M
-44.54%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$56.9B
810.37%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.4B
230.07%
29.56
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$639.8B
440.46%
49.53
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$124.7B
182.21%
31.34
39.46%

Institutional Holdings

  • Artal Group S A

    14.12%
  • FMR Inc

    13.29%
  • T. Rowe Price Associates, Inc.

    10.29%
  • Samsara BioCapital, LLC

    8.51%
  • Redmile Group, LLC

    8.05%
  • BlackRock Inc

    6.28%

Company Information

scholar rock® is a biotechnology company focused on discovering and developing a new class of biologic therapies called "niche modulators" that selectively target the activation of growth factors in the disease microenvironment. our initial proprietary and partnered drug discovery programs target specific growth factors, including members of the tgf-beta superfamily, which play a fundamental role in regulating cell growth and differentiation and are present in the microenvironments of significant diseases such as fibrosis, diseases of the musculoskeletal systems, and autoimmune diseases. the company’s therapeutic approach is enabled by discoveries made by scholar rock’s scientific founders—professors timothy springer, phd, and leonard zon, md, both of children's hospital boston and harvard medical school—related to the molecular mechanisms of growth factor activation. scholar rock is backed by leading life sciences investors, including polaris partners, arch venture partners, timothy s

Organization
Scholar Rock Holding Corp
Employees
150
CEO
Dr. Jay Thomas Backstrom M.D., M.P.H.
Industry
Health Technology

FAQs